A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy.
about
Efavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsHIV protease inhibitors: a review of molecular selectivity and toxicitySystematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reactionPilot, randomized study assessing safety, tolerability and efficacy of simplified LPV/r maintenance therapy in HIV patients on the 1 PI-based regimenEffectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysisThe risk of virologic failure decreases with duration of HIV suppression, at greater than 50% adherence to antiretroviral therapy.Baseline natural killer and T cell populations correlation with virologic outcome after regimen simplification to atazanavir/ritonavir alone (ACTG 5201).Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level.HIV-associated lipodystrophy: impact of antiretroviral therapy.Single genome sequencing of HIV-1 gag and protease resistance mutations at virologic failure during the OK04 trial of simplified versus standard maintenance therapyEfficacy and safety of lopinavir/ritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women.Prevalence of and risk factors for lipodystrophy among HIV-infected patients receiving combined antiretroviral treatment in the Asia-Pacific region: results from the TREAT Asia HIV Observational Database (TAHOD).Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patientsProtease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial.Boosted protease inhibitor monotherapy in HIV-infected adults: outputs from a pan-European expert panel meeting.Lopinavir plasma concentrations and virological outcome with lopinavir-ritonavir monotherapy in HIV-1-infected patientsRegimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes.HIV protease inhibitors: recent clinical trials and recommendations on use.Ritonavir-boosted protease inhibitors in HIV therapy.Protease inhibitor monotherapy: what is its role?Geographic and temporal trends of transmitted HIV-1 drug resistance among antiretroviral-naïve subjects screening for two clinical trials in North America and Western Europe.Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor-based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials.Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials.Effect of Monotherapy with Darunavir/Ritonavir on Viral Load in Seminal Fluid, and Quality Parameters of Semen in HIV-1-Positive Patients.Improvement of lipoatrophy by switching from efavirenz to lopinavir/ritonavir.Switching to darunavir/ritonavir monotherapy vs. triple-therapy on body fat redistribution and bone mass in HIV-infected adults: the Monarch randomized controlled trial.Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy.Monotherapy with Lopinavir/Ritonavir as maintenance after HIV-1 viral suppression: results of a 96-week randomized, controlled, open-label, pilot trial (KalMo study).Costs of adverse events among patients with HIV infection treated with nonnucleoside reverse transcriptase inhibitors.High quality of life, treatment tolerability, safety and efficacy in HIV patients switching from triple therapy to lopinavir/ritonavir monotherapy: A randomized clinical trial.HIV protease inhibitors: present and future
P2860
Q28081266-85E88AF7-EB54-4930-AD30-ACF4EA9D0A93Q28082749-A9AE415B-1448-4690-8DCE-61E76AA63936Q28533379-3F0AB667-A9A8-40AC-BE68-B282342656EFQ28741214-46B8082D-1DAD-45DC-B640-F73EA9004D1AQ28742423-074F3734-82B3-4462-A6E3-B825C71535DBQ33507274-3C57FB47-A95F-4BDC-9966-1CAE8C9B8E3FQ33572705-86FBEBF5-E49B-4FA0-A018-51B6F7AA6295Q34283336-B4DEA24F-1151-41C4-ADB6-1E5F5BDA8C19Q34655845-32185AC4-A790-4C6B-A9EA-C3D57E10A7A5Q35158051-3DBF8172-05F7-4DEF-9997-4B5A25F1FAB0Q35597592-F4F981EF-640E-43F5-A5AC-C64E03B0FAE2Q35898696-291D5731-6D88-443D-B8FE-1124CDAF1F4DQ36278470-0FD3E904-4AA2-4C66-A8A9-EDF853C469FAQ36613143-C6339E72-93B7-4EFA-84F4-F8CDDACECF5CQ36722728-260D2BCC-4FF8-4516-A8E8-061CA49A6B07Q37036468-C14B457C-07F2-44C3-A690-BDFAAB63636FQ37189025-44A43743-0A61-42B5-A91C-AE8529B6EC0DQ37519715-C9279657-A737-4FDA-936B-1D672FD5D9A4Q37866319-20179CDA-B162-4AD7-B4C3-35C2A4F77999Q37987855-D6DDFF57-B832-4AE2-9FD4-78521A5ADC10Q38450409-72FB0C99-1575-4DB6-ACC7-99BBBC9DC5E2Q38811335-631AD6E7-9BCD-4A79-88DB-85DF808081D6Q39515202-F648745C-197D-4904-88EB-D0FDB76835B7Q40605067-A606FBF7-E9AB-4487-8D55-9CE3E25032F9Q40709842-0772B730-31EC-4DD8-B701-6363352B4BACQ42241185-3D3F7D31-E1A1-48A1-962C-687BE6BB0986Q43102710-018D4D10-48CF-4693-8E87-0C2570D28B99Q43172783-A00205DE-2E31-4199-B2DD-951F6936DF0DQ43410386-05A30240-4F38-4D7D-B139-093419D9A7D4Q52591808-B19540CD-3788-4AA9-AA4C-5085BF23C0BDQ58290794-779BBB4D-BA0E-48BD-8AE1-1044ECF4BBE5
P2860
A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
A 96-week comparison of lopina ...... efavirenz combination therapy.
@en
type
label
A 96-week comparison of lopina ...... efavirenz combination therapy.
@en
prefLabel
A 96-week comparison of lopina ...... efavirenz combination therapy.
@en
P2093
P356
P1476
A 96-week comparison of lopina ...... efavirenz combination therapy
@en
P2093
Barbara A da Silva
Barry M Bernstein
George J Hanna
Martin S King
Nicholaos C Bellos
Norbert Gilmore
Robert A Myers
Scott C Brun
P304
P356
10.1086/589622
P407
P577
2008-07-01T00:00:00Z